This article needs additional citations for verification. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: – ···scholar·JSTOR(November 2012) (Learn how and when to remove this template message)
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]
References[]
^"Dusigitumab"(PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.